Citigroup
ELVN icon

Citigroup’s Enliven Therapeutics ELVN Stock Holding History

Citigroup’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.09M Sell
23,791
-6,921
-23% -$377K ﹤0.01% 3253
2026
Q2 		$1.56M Buy
30,712
+16,011
+109% +$680K ﹤0.01% 3120
2026
Q1 		$576K Sell
14,701
-3,788
-20% -$105K ﹤0.01% 3460
2025
Q4 		$285K Buy
18,489
+6,743
+57% +$134K ﹤0.01% 3836
2025
Q3 		$240K Sell
11,746
-6,393
-35% -$129K ﹤0.01% 3917
2025
Q2 		$364K Sell
18,139
-12,700
-41% -$240K ﹤0.01% 3799
2025
Q1 		$607K Sell
30,839
-2,709
-8% -$58.3K ﹤0.01% 3574
2024
Q4 		$755K Buy
33,548
+4,650
+16% +$121K ﹤0.01% 3564
2024
Q3 		$738K Buy
28,898
+18,296
+173% +$424K ﹤0.01% 3488
2024
Q2 		$248K Buy
10,602
+2,769
+35% +$58.3K ﹤0.01% 3783
2024
Q1 		$138K Buy
7,833
+427
+6% +$6.55K ﹤0.01% 4164
2023
Q4 		$102K Buy
7,406
+4,059
+121% +$49.7K ﹤0.01% 4192
2023
Q3 		$45.7K Sell
3,347
-7,476
-69% -$126K ﹤0.01% 4172
2023
Q2 		$221K Sell
10,823
-440
-4% -$8.89K ﹤0.01% 3847
2023
Q1 		$247K Buy
+11,263
New +$229K ﹤0.01% 3602
2021
Q2 		– Sell
-127
Closed -$4K – 6188
2021
Q1 		$4K Sell
127
-227
-64% -$11.5K ﹤0.01% 5936
2020
Q4 		$31K Buy
354
+294
+490% +$24.7K ﹤0.01% 6366
2020
Q3 		$5K Sell
60
-108
-64% -$9.7K ﹤0.01% 6996
2020
Q2 		$19K Buy
+168
New +$18.8K ﹤0.01% 6650

Other funds holding ELVN

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Citigroup's ELVN Position: Q3 2026 in Review

Citigroup reduced its Enliven Therapeutics (ELVN) stake by 23% in Q3 2026, selling an estimated $377K and leaving 23,791 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #3253.

Citigroup first reported a position in ELVN in Q2 2020 and has held it in 19 quarters since. The position peaked at $1.56M in Q2 2026. 38 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • Citigroup held 23,791 shares of Enliven Therapeutics worth $1.09M as of Q3 2026.
  • Citigroup sold 6,921 Enliven Therapeutics shares in Q3 2026, an estimated $377K.
  • Enliven Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3253 holding.
  • Citigroup first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • Citigroup's Enliven Therapeutics position peaked at $1.56M in Q2 2026.
  • 38 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.